Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is curable with first-line chemoimmunotherapy but patients with relapsed/refractory (R/R) DLBCL still face a poor prognosis. For patients with R/R DLBCL, the complete response rate to traditional next-line therapy is only 7% and the median overall su...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Yuan-Yuan, Chen, Pan-Pan, Yuan, Xiang-Gui, Zhao, Ai-Qi, Liang, Yun, Liu, Hui, Qian, Wen-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294888/
https://www.ncbi.nlm.nih.gov/pubmed/35979312
http://dx.doi.org/10.12998/wjcc.v10.i19.6555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294888/
https://www.ncbi.nlm.nih.gov/pubmed/35979312
http://dx.doi.org/10.12998/wjcc.v10.i19.6555

Ejemplares similares